Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research

Plain-language summary

This study investigates how imaging can be used to assess the invasiveness of hepatocellular carcinoma (a type of liver cancer). Patients aged 18-80 whose initial treatment is curative-intent liver resection (hepatectomy) can take part. It is a study without an assigned phase and is still enrolling participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Chinese PLA General Hospital

Intervention

Hepatectomy

Start date

1/1/2023

Estimated completion

12/31/2029

Countries

China

Related genes

Locations

• Beijing, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* According to the WHO classification, the pathological diagnosis is hepatocellular carcinoma.
* The initial treatment is curative-intent hepatectomy.
* There is no evidence of major vascular/hepatic portal invasion, extrahepatic/lymph node metastasis, or other malignant tumors.
* Age 18-80 years old.

Exclusion Criteria:

· Not meeting any one of the inclusion criteria or being unwilling/unable to follow-up.